Back to Clinical Trials

Brief Title: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

INTRODUCTION

  • Org Study ID: KlusPharma
  • Secondary ID: N/A
  • NTC ID: NCT03602079
  • Sponsor: Klus Pharma Inc.

BRIEF SUMMARY

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

DETAILED DESCRIPTION

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).

  • Overall Status
    Recruiting
  • Start Date
    July 16, 2018
  • Phase
    Phase 1, Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Phase I: Maximum Tolerated Dose

Primary Outcome 1 - Timeframe: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Primary Outcome 2 - Measure: Phase II: Percentage of patients with an Objective Response Rate (ORR) [Complete Response (CR) + Partial Response (PR)]

Primary Outcome 2 - Timeframe: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

CONDITION

  • HER2-positive Breast Cancer
  • HER2 Gene Mutation
  • HER-2 Gene Amplification
  • HER2 Positive Gastric Cancer
  • Salivary Gland Cancer
  • Salivary Gland Tumor
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Lung Cancer
  • Colo-rectal Cancer
  • Rare Diseases
  • Solid Tumor
  • Recurrent Gastric Cancer
  • Recurrent Colon Cancer
  • Recurrent Breast Cancer
  • Head and Neck Cancer
  • Head and Neck Carcinoma
  • Bladder Cancer
  • Cervical Cancer
  • Liver Cancer
  • Bile Duct Cancer
  • Urologic Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Recurrent Prostate Cancer
  • Rectal Cancer
  • Recurrent Ovarian Carcinoma
  • Recurrent Renal Cell Cancer
  • Rectal Cancer Stage II
  • Rectal Cancer Stage I
  • Rectal Cancer Stage III
  • Skin Cancer
  • Mouth Cancer
  • Lip Cancer Stage I
  • Tongue Cancer
  • Breast Neoplasm Malignant Primary
  • Larynx Cancer
  • Tonsil Cancer
  • Palate Cancer
  • Mucoepidermoid Carcinoma
  • Primary Peritoneal Carcinoma
  • Mucinous Adenocarcinoma Gastric
  • Mucinous Breast Cancer Recurrent
  • Cholangiocarcinoma

ELIGIBILITY

Inclusion Criteria:
Phase I
Patients must meet the following criteria for inclusion into the study:
Patients must be able to provide documented voluntary informed consent.

- Male or female patient ≥ 18 years.

- Histologically documented, incurable, locally advanced or metastatic cancer.

- Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC.

- Patients should have no available therapy likely to convey clinical benefit.

- Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.

- Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).

- Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.

- ECOG Performance Status ≤ 1.

- Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy.

- Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
Phase II
Patients must meet the following criteria for inclusion into the study:
Patients must be able to provide documented voluntary informed consent.

- Male or female patient ≥ 18 years.

- Histologically documented, incurable, locally advanced or metastatic cancer.

- Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC.
Regarding previous therapy:
5.1. Cohort 1: HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC 3+) breast cancer: patients should have progressed after at least 2 previous HER2 directed regimens in metastatic disease with approved therapies.
5.2. Cohort 2: HER2 positive (IHC 2+ with FISH confirmation and IHC 3+) gastric cancer: patients should have progressed after at least 1 previous HER2 directed regimens in metastatic disease with approved therapies.
5.3. Cohort 3: HER2 low expressing (IHC 1+ and IHC 2+ without FISH confirmation) breast cancer: patients should have no available therapy likely to convey clinical benefit.
5.4. Cohort 4: all cancers other than breast cancer with low HER2 expression (IHC 1+ and IHC 2+ without FISH confirmation) and HER2 positive (IHC 2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer: patients should have no available therapy likely to convey clinical benefit.
Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.

- Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).

- Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.

- ECOG Performance Status ≤ 1.

- Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy.

- Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
Exclusion Criteria:
Phase I:
Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).

- History of Grade ≥ 3 hypersensitivity reaction to trastuzumab.

- History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued.

- Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.

- Require supplemental oxygen for daily activities.

- Documented Grade ≥ 2 peripheral neuropathy.

- Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug.

- Any experimental therapy within 4 weeks of first infusion of study drug.

- Any major surgical procedure within 4 weeks of first infusion of study drug.

- Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded.

- Have known prior positive test results for human immunodeficiency virus.

- Uncontrolled hypertension or diabetes.

- Pregnancy or lactation.

- Resting corrected QT interval (QTc) > 470 ms at baseline.

- Left ventricular ejection fraction (LVEF) < 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. - Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.
Phase II:
Any patient who was treated in the Phase I part of this study.

- Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).

- History of Grade ≥ 3 hypersensitivity reaction to trastuzumab.

- History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued.

- Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.

- Require supplemental oxygen for daily activities.

- Documented Grade ≥ 2 peripheral neuropathy.

- Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug.

- Any experimental therapy within 4 weeks of first infusion of study drug.

- Any major surgical procedure within 4 weeks of first infusion of study drug.

- Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded.

- Have known prior positive test results for human immunodeficiency virus.

- Uncontrolled hypertension or diabetes.

- Pregnancy or lactation.

- Resting QTc > 470 ms at baseline.

- LVEF < 45% determined by ECHO or MUGA scan. - Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Jordi Rodon Ahnert, MD, PhD

Role: Study Chair

Affiliation: MD Anderson

Overall Contact

Name: Jordi Rodon Ahnert, MD, PhD

Phone: 609-662-1913

Email: Clinicaltrialinfo@kluspharma.com

LOCATION

Facility Status Contact
Facility: Florida Cancer Specialists & Research Institute
Sarasota, Florida 34232
United States
Status: Recruiting Contact: Contact
Donna L Jones, BSN, RN, OCN,
941-377-9993
clcruz@bidmc.harvard.edu
Facility: Beth Israel Deaconess Medical Center Cancer Center
Boston, Massachusetts 02215
United States
Status: Recruiting Contact: Contact
Cassandra Cruz
617-975-7411
davisv@karmanos.org
Facility: Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Status: Recruiting Contact: Contact
Valerie Davis
313-576-9370
ckats@researchcra.com
Facility: Clinical Research Alliance, Inc.
Lake Success, New York 11042
United States
Status: Recruiting Contact: Contact
Colleen Kats
405-271-8778
SCC-Clinical-Trials-Office@ouhsc.edu
Facility: Stephenson Cancer Center
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: Contact
Dana Suters
503-215-2614
Christina.Lopez4@providence.org
Facility: Providence Cancer Institute
Portland, Oregon 97213
United States
Status: Recruiting Contact: Contact
Christina Lopez
972-566-3000
referral@marycrowley.org
Facility: Mary Crowley Cancer Research Centers - Medical City
Dallas, Texas 75230
United States
Status: Recruiting Contact: Contact
Amy Jordan
713-563-1930
isabel.jimenez@startsa.com
Facility: The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: Contact
Jordi Rodon Ahnert, M.D., PhD
210-593-5265
Alexander.Spira@usoncology.com
Facility: South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas 78229
United States
Status: Recruiting Contact: Contact
Isabel Jimenez, RN, MSN
703-280-5390
Facility: Virginia Cancer Specialist
Fairfax, Virginia 22031
United States
Status: Recruiting Contact: Contact
Alexander Spira, MD, PhD,FACP